Rifampin was shown in vitro to decrease the amphotericin B minimal inhibitory concentrations of all of 10 strains of Coccidioides immitis tested. These decreases ranged from two-to fourfold and occurred with rifampin concentrations of 10 to 40 Ag/ml. Rifampin alone was without effect.
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At the present time, amphotericin B is the only therapeutic agent available for the treatment of coccidioidomycosis. In the localized pulmonary form of the disease no specific therapy is used, because the toxicity associated with the antibiotic administration seems unwarranted in this self-limited process. In the chronic pulmonary infection with cavitation, amphotericin B and surgical resection are frequently necessary (5, 11) . In the disseminated disease, a mortality rate of about one-half still remains despite antifungal therapy and further, when the central nervous system is involved, cures are extremely rare (8) .
Recently, Medoff and co-workers (6, 7) have shown an interaction of amphotericin B with rifampin in the inhibition of the yeast-phase of Histoplasma capsulatum, and with 5-fluorcytosine in the inhibition of candida, cryptococcus, and saccharomyces strains.
The Rifampin was prepared by dissolving the contents of a 300-mg capsule of the drug (Rimactane; CIBA-Geigy) in 10 ml of absolute alcohol. Further dilutions were then made in water.
Susceptibility testing. Antibiotic-susceptibility testing was done in 1-ounce screw-capped glass prescription bottles. Sterilized melted Sabouraud agar (4.5 ml) and 0.5 ml of antibiotic or antibiotic combinations were dispensed and the bottles were placed on their sides to allow the agar to solidify. The arthrospore-mycelial suspension (0.1 ml) described above was added and the bottles were incubated at 37 C for 3 to 5 days. Counts were made of the colonies when they were just visable to the unaided eye. Each concentration of antibiotic was tested in duplicate bottles. The minimal inhibitory concentration (MIC) was determined on the basis of complete absence of growth.
RESULTS
The MICs of amphotericin B for the 10 strains of C. immitis varied from 0.8 to 3.2 ,ug/ml (Table 1 ).
Rifampin alone was tested against the 10 strains in concentrations up to 40 yg/ml and in no case was there any inhibition of growth (not shown in Table 1 ).
The MICs of amphotericin B in the presence of varying concentrations of rifampin were then assayed ( In this study, the combined effect of rifampin and amphotericin B was shown directly by inhibition of colonial growth. In the study by Kobayashi et al. (6) , the combined effect of these two drugs against the yeast-phase of H. capsulatum was assayed on the basis of decreases in tritiated guanine uptake into ribonucleic acid. In addition, however, they state that similar results were obtained by the colony count method.
It is of course unknown whether the combined effect of amphotericin B and rifampin would be useful in the treatment of patients with coccidioidomycosis. This question awaits appropriate animal and then controlled clinical trials. Two notes of caution should be considered in evaluating such a program. First, it was demonstrated by both in vitro and in vivo methods that rifampin inhibits manifestations of the cell-mediated immune' reaction (4) . As this immune response is central to the defense against fungal infections its suppression would adversely affect recovery. However, in disseminated coccidioidomycosis, specific cellmediated immunity is defective and so the rifampin effect might not be further detrimen-ANTIMICROB. AG. CHEMiorHimR. tal. Second, the development of resistance to rifampin has proved a problem in the treatment of certain bacterial infections (3) and such might also arise during combined therapy of coccidioidomycosis with rifampin and amphotericin B.
The concentrations of rifampin (10 to 40
Wg/ml) shown here to decrease the amphotericin B MICs are similar to those obtained in patients given the usual therapeutic doses. Following a single 600-mg oral rifampin dose, peak serum levels range from 5.5 to 32,g/ml in one study (9) and 3.4 to 16.9 ug/ml in another (10) . Thus, serum concentrations of rifampin shown in vitro to be effective would be achievable in patients.
In contrast, cerebrospinal fluid levels of rifampin are low after oral therapy, even in the presence of inflammation, and accordingly, central nervous system infection would pose an unique problem (2) . It should be noted that such is also the case with amphotericin B (1), and administration of this antifungal agent directly into the cerebrospinal fluid is essential in the treatment of coccidioidal meningitis. Possibly rifampin could be admixed with amphotericin B for intrathecal administration.
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